[{"data":1,"prerenderedAt":159},["ShallowReactive",2],{"drug-frovatriptan":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":62,"warnings":72,"renal":80,"monitoring":81,"interactions":82,"review":83,"examples":86,"atc":92,"iran":94,"links":101,"populations":118,"usApproval":154},"frovatriptan",1,{"fa":7,"en":8},"فرواتریپتان","Frovatriptan","nervous-system",{"fa":11,"en":12},"تریپتان (آگونیست 5-HT1B\u002F1D)","Triptan (5-HT1B\u002F1D agonist)",[14],{"name":15,"market":16},"Frova","US",[18,19,7],"frova","فروا",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-2-5","tablet","oral","2.5 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},2.5,"mg",false,[16],[32],{"source":33,"section":34},"fda-frovatriptan","3",[36],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":48,"limits":51,"notes":55},"acute","migraine-acute",{"fa":40,"en":41},"حمله حاد میگرن بزرگسال — ۲٫۵ mg با مایعات","Acute migraine, adults — 2.5 mg with fluids",{"minAge":43},{"value":44,"unit":45},18,"year","fixed",{"perDose":27,"dosesPerDay":5},[49],{"source":33,"section":50},"2",{"maxPerDay":52,"refs":53},7.5,[54],{"source":33,"section":50},[56],{"text":57,"refs":60},{"fa":58,"en":59},"اگر پس از بهبود اولیه بازگشت: دوز دوم با دست‌کم ۲ ساعت فاصله؛ حداکثر ۳ قرص (۷٫۵ mg) در ۲۴ ساعت.","If it recurs after initial relief: second dose at least 2 h later; max 3 tablets (7.5 mg) in 24 h.",[61],{"source":33,"section":50},[63],{"id":64,"severity":65,"text":66,"refs":69},"ci","block",{"fa":67,"en":68},"بیماری ایسکمیک کرونر یا وازواسپاسم کرونر (پرینزمتال)؛ WPW یا آریتمی مسیر فرعی؛ سابقه سکته، TIA یا میگرن همی‌پلژیک\u002Fبازیلار؛ بیماری عروق محیطی؛ بیماری ایسکمیک روده؛ فشار خون کنترل‌نشده؛ تریپتان یا ارگوت دیگر ظرف ۲۴ ساعت؛ حساسیت.","Ischaemic coronary disease or coronary vasospasm (Prinzmetal); WPW or accessory-pathway arrhythmias; history of stroke, TIA or hemiplegic\u002Fbasilar migraine; peripheral vascular disease; ischaemic bowel disease; uncontrolled hypertension; another triptan or ergot within 24 h; hypersensitivity.",[70],{"source":33,"section":71},"4",[73],{"text":74,"refs":77},{"fa":75,"en":76},"ایسکمی و انفارکتوس قلب؛ آریتمی؛ احساس فشار قفسه سینه، گلو یا فک؛ رویداد عروق مغزی؛ سردرد ناشی از مصرف زیاد دارو؛ سندرم سروتونین؛ افزایش فشار خون.","Myocardial ischaemia and infarction; arrhythmias; chest\u002Fthroat\u002Fjaw tightness; cerebrovascular events; medication-overuse headache; serotonin syndrome; increased blood pressure.",[78],{"source":33,"section":79},"5",[],[],[],{"status":84,"reviewer":85,"date":85},"unverified",null,[87],{"regimen":37,"formulation":22,"input":88,"expect":91},{"ageYears":89,"weightKg":90},35,65,{"perDose":27,"tabletsPerDoseRounded":5},[93],"N02CC07",{"status":95,"refs":96},"not-found",[97],{"source":98,"section":99,"url":100},"darooyab-generic","G-857\u002FFrovatriptan","https:\u002F\u002Fwww.darooyab.ir\u002FG-857\u002FFrovatriptan",[102,106,110,113,116],{"kind":103,"url":104,"label":105},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=216998","ANDA216998",{"kind":107,"url":108,"label":109},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=d303af88-e0c1-4fb2-ba8e-83b7e6d163cd","FDA Frovatriptan",{"kind":111,"url":112,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa604013.html",{"kind":114,"url":115,"label":93},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N02CC07",{"kind":117,"url":100,"label":8},"darooyab",{"pregnancy":119,"lactation":128,"pediatric":136,"geriatric":145},{"level":120,"text":121,"quote":124,"refs":125},"caution",{"fa":122,"en":123},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate data on the developmental risk associated with the use of frovatriptan succinate in pregnant women.",[126],{"source":33,"section":127},"8.1",{"level":120,"text":129,"quote":132,"refs":133},{"fa":130,"en":131},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of frovatriptan in human milk, the effects of frovatriptan on the breastfed infant, or the effects of frovatriptan on milk production.",[134],{"source":33,"section":135},"8.2",{"level":137,"text":138,"quote":141,"refs":142},"not-established",{"fa":139,"en":140},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","The safety and effectiveness in pediatric patients have not been established.",[143],{"source":33,"section":144},"8.4",{"level":146,"text":147,"quote":150,"refs":151},"ok",{"fa":148,"en":149},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No dosage adjustment is necessary.",[152],{"source":33,"section":153},"8.5",{"kind":155,"refs":156,"id":105},"ANDA",[157],{"source":33,"section":158},"SPL approval \u002F marketing category",1792191545986]